• About
  • Advertise
  • Privacy & Policy
  • Contact
HK Businesswire
  • Home
  • News
    • All
    • Business
    • Politics
    • PR Newswire
    • Science
    • World
    ASH 2025 Oral Presentation: Innovent Biologics Announces Initial Results of the First-in-Human Phase 1 Study of Trispecific Antibody IBI3003 in Relapsed or Refractory Multiple Myeloma

    ASH 2025 Oral Presentation: Innovent Biologics Announces Initial Results of the First-in-Human Phase 1 Study of Trispecific Antibody IBI3003 in Relapsed or Refractory Multiple Myeloma

    Federation secures prestigious Victorian International Education Award wins

    Federation secures prestigious Victorian International Education Award wins

    Investment of Approx. USD 460,000 for the Development of a Prototype Mpox Detection Test with NIPRO, TBA, Japan Institute for Health Security and others

    Investment of Approx. USD 460,000 for the Development of a Prototype Mpox Detection Test with NIPRO, TBA, Japan Institute for Health Security and others

    RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) delivers statistically significant and clinically meaningful improvement in overall survival benefit for Asian patients with EGFR-mutated non-small cell lung cancer in the Phase 3 MARIPOSA study

    RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) delivers statistically significant and clinically meaningful improvement in overall survival benefit for Asian patients with EGFR-mutated non-small cell lung cancer in the Phase 3 MARIPOSA study

    TenPay Global and Mastercard collaborate to enable fast and secure remittances to Weixin Pay

    TenPay Global and Mastercard collaborate to enable fast and secure remittances to Weixin Pay

    Dulwich College Ranjit Murugason Sustainability Fund Secures Renewed Support from LGT Bank Singapore to Advance Student-Led Initiatives

    Dulwich College Ranjit Murugason Sustainability Fund Secures Renewed Support from LGT Bank Singapore to Advance Student-Led Initiatives

    Trending Tags

    • Trump Inauguration
    • United Stated
    • White House
    • Market Stories
    • Election Results
  • PR Newswire
  • Business
  • World
  • Entertainment
  • Sports
  • Tech
    • All
    • Apps
    • Gadget
    • Mobile
    • Startup

    Meituan Reports Q3 2025 Results: Revenue Reaches RMB95.5 Billion as Annual Transacting Users Surpass 800 Million

    Xiaomi Founder Lei Jun Boosts Stake as Company Ramps Up Buybacks, Signaling Confidence

    Ant Group’s Multimodal AI Assistant LingGuang Surpasses 1 Million Downloads in Four Days

    Xiaomi Produces 500,000th EV in Record Time, CEO Lei Jun Pledges Focus on Safety and Delivery

    Morrison Foerster Report: ESG Committees and Climate Policy Gaining Traction Among Asia’s Largest GPs

    Xiaomi’s Double 11 GMV Surges Past RMB 29 Billion as It Claims Top Domestic Phone Sales for Third Year

    Trending Tags

    • Nintendo Switch
    • CES 2017
    • Playstation 4 Pro
    • Mark Zuckerberg
  • Feature
No Result
View All Result
  • Home
  • News
    • All
    • Business
    • Politics
    • PR Newswire
    • Science
    • World
    ASH 2025 Oral Presentation: Innovent Biologics Announces Initial Results of the First-in-Human Phase 1 Study of Trispecific Antibody IBI3003 in Relapsed or Refractory Multiple Myeloma

    ASH 2025 Oral Presentation: Innovent Biologics Announces Initial Results of the First-in-Human Phase 1 Study of Trispecific Antibody IBI3003 in Relapsed or Refractory Multiple Myeloma

    Federation secures prestigious Victorian International Education Award wins

    Federation secures prestigious Victorian International Education Award wins

    Investment of Approx. USD 460,000 for the Development of a Prototype Mpox Detection Test with NIPRO, TBA, Japan Institute for Health Security and others

    Investment of Approx. USD 460,000 for the Development of a Prototype Mpox Detection Test with NIPRO, TBA, Japan Institute for Health Security and others

    RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) delivers statistically significant and clinically meaningful improvement in overall survival benefit for Asian patients with EGFR-mutated non-small cell lung cancer in the Phase 3 MARIPOSA study

    RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) delivers statistically significant and clinically meaningful improvement in overall survival benefit for Asian patients with EGFR-mutated non-small cell lung cancer in the Phase 3 MARIPOSA study

    TenPay Global and Mastercard collaborate to enable fast and secure remittances to Weixin Pay

    TenPay Global and Mastercard collaborate to enable fast and secure remittances to Weixin Pay

    Dulwich College Ranjit Murugason Sustainability Fund Secures Renewed Support from LGT Bank Singapore to Advance Student-Led Initiatives

    Dulwich College Ranjit Murugason Sustainability Fund Secures Renewed Support from LGT Bank Singapore to Advance Student-Led Initiatives

    Trending Tags

    • Trump Inauguration
    • United Stated
    • White House
    • Market Stories
    • Election Results
  • PR Newswire
  • Business
  • World
  • Entertainment
  • Sports
  • Tech
    • All
    • Apps
    • Gadget
    • Mobile
    • Startup

    Meituan Reports Q3 2025 Results: Revenue Reaches RMB95.5 Billion as Annual Transacting Users Surpass 800 Million

    Xiaomi Founder Lei Jun Boosts Stake as Company Ramps Up Buybacks, Signaling Confidence

    Ant Group’s Multimodal AI Assistant LingGuang Surpasses 1 Million Downloads in Four Days

    Xiaomi Produces 500,000th EV in Record Time, CEO Lei Jun Pledges Focus on Safety and Delivery

    Morrison Foerster Report: ESG Committees and Climate Policy Gaining Traction Among Asia’s Largest GPs

    Xiaomi’s Double 11 GMV Surges Past RMB 29 Billion as It Claims Top Domestic Phone Sales for Third Year

    Trending Tags

    • Nintendo Switch
    • CES 2017
    • Playstation 4 Pro
    • Mark Zuckerberg
  • Feature
No Result
View All Result
HK Businesswire
No Result
View All Result
Home News Business

CK Hutchison Considers Spinning Off Global Telecom Assets with Potential London Listing

Purton L by Purton L
28 March 2025
in Business, Tech
0
Net profit at CK Hutchison down 27pc
0
SHARES
10
VIEWS
Share on FacebookShare on Twitter

Conglomerate Aims to Unlock Value as Market Conditions Stabilize

CK Hutchison Holdings Ltd. is exploring a potential spin-off of its extensive international telecom portfolio, with early-stage plans to list the new entity in London, according to sources familiar with the matter. The move would consolidate its European and Asian telecom operations, including assets in the UK, Italy, Sweden, Austria, Indonesia, and Vietnam, into a standalone vehicle. The Hong Kong-based conglomerate is reportedly working with advisors to assess timing and structure, though discussions remain preliminary.

The proposed spin-off is aimed at unlocking shareholder value and streamlining CK Hutchison’s diverse business portfolio, which spans ports, retail, infrastructure, and telecommunications. The company has spent years merging and restructuring telecom operations across Europe, including the recent merger of its UK arm Three with Vodafone. A listing in London would mark a significant vote of confidence in the UK capital market, which has struggled in recent years to attract high-profile IPOs.

If executed, the listing could come as early as 2025, depending on market conditions. CK Hutchison is expected to retain a strategic stake in the spun-off entity, allowing it to maintain influence while providing room for external investors to participate. Analysts view the move as part of a broader trend among Asian conglomerates seeking to realign capital structures and reduce conglomerate discounts through separation of business lines.

Tags: capital marketsCK HutchisonIPOLondon listingtelecom spinoffThree UKVodafone merger
Purton L

Purton L

Read More

HK stocks end week up amid a mainland chip surge

HK stocks end week up amid a mainland chip surge

5 December 2025
HK, mainland stocks mixed as Nikkei takes a hit

HK, mainland stocks mixed as Nikkei takes a hit

5 December 2025
  • Trending
  • Comments
  • Latest
Tai Po fire death toll climbs to 44, 56 injured

Tai Po fire death toll climbs to 44, 56 injured

26 November 2025
No for now on women deacons, Vatican commission says

No for now on women deacons, Vatican commission says

4 December 2025

Ant Group’s Multimodal AI Assistant LingGuang Surpasses 1 Million Downloads in Four Days

23 November 2025
Hang Seng Indexes Company and Cyberport Partner to Drive Gen-AI Adoption in Index Calculation

Hang Seng Indexes Company and Cyberport Partner to Drive Gen-AI Adoption in Index Calculation

4 November 2025
ASH 2025 Oral Presentation: Innovent Biologics Announces Initial Results of the First-in-Human Phase 1 Study of Trispecific Antibody IBI3003 in Relapsed or Refractory Multiple Myeloma

ASH 2025 Oral Presentation: Innovent Biologics Announces Initial Results of the First-in-Human Phase 1 Study of Trispecific Antibody IBI3003 in Relapsed or Refractory Multiple Myeloma

8 December 2025
Federation secures prestigious Victorian International Education Award wins

Federation secures prestigious Victorian International Education Award wins

8 December 2025
Investment of Approx. USD 460,000 for the Development of a Prototype Mpox Detection Test with NIPRO, TBA, Japan Institute for Health Security and others

Investment of Approx. USD 460,000 for the Development of a Prototype Mpox Detection Test with NIPRO, TBA, Japan Institute for Health Security and others

8 December 2025
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) delivers statistically significant and clinically meaningful improvement in overall survival benefit for Asian patients with EGFR-mutated non-small cell lung cancer in the Phase 3 MARIPOSA study

RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) delivers statistically significant and clinically meaningful improvement in overall survival benefit for Asian patients with EGFR-mutated non-small cell lung cancer in the Phase 3 MARIPOSA study

8 December 2025

Recent News

ASH 2025 Oral Presentation: Innovent Biologics Announces Initial Results of the First-in-Human Phase 1 Study of Trispecific Antibody IBI3003 in Relapsed or Refractory Multiple Myeloma

ASH 2025 Oral Presentation: Innovent Biologics Announces Initial Results of the First-in-Human Phase 1 Study of Trispecific Antibody IBI3003 in Relapsed or Refractory Multiple Myeloma

8 December 2025
Federation secures prestigious Victorian International Education Award wins

Federation secures prestigious Victorian International Education Award wins

8 December 2025
Investment of Approx. USD 460,000 for the Development of a Prototype Mpox Detection Test with NIPRO, TBA, Japan Institute for Health Security and others

Investment of Approx. USD 460,000 for the Development of a Prototype Mpox Detection Test with NIPRO, TBA, Japan Institute for Health Security and others

8 December 2025
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) delivers statistically significant and clinically meaningful improvement in overall survival benefit for Asian patients with EGFR-mutated non-small cell lung cancer in the Phase 3 MARIPOSA study

RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) delivers statistically significant and clinically meaningful improvement in overall survival benefit for Asian patients with EGFR-mutated non-small cell lung cancer in the Phase 3 MARIPOSA study

8 December 2025
HK Businesswire

Stay ahead with the latest insights on Hong Kong’s economy, finance, and investments. From market trends to policy updates, we bring you in-depth analysis and expert opinions.

📩 Subscribe to our newsletter for exclusive updates.
📍 Follow us on social media for real-time news.
📧 Contact us: info@hongkong-invest.com

Follow Us

  • About
  • Advertise
  • Privacy & Policy
  • Contact

© 2025 by HKBusinesswire.com

No Result
View All Result

© 2025 by HKBusinesswire.com